10-K: Ardent Health Reports Mixed 2025 Results Amid Rising Costs, New Laws

Ardent Health, Inc. reported a 6.0% revenue increase in 2025 but saw net income decline significantly due to surging professional liability costs and the impact of new federal healthcare legislation.

Summary

• Total revenue increased by 6.0% to $6.32 billion in 2025, up from $5.97 billion in 2024.
• Adjusted admissions grew by 2.3%, and net patient service revenue per adjusted admission increased by 3.5%.
• Net income attributable to Ardent Health, Inc. decreased to $135.8 million in 2025 from $210.3 million in 2024.
• Basic earnings per share (EPS) was $0.96 in 2025, down from $1.59 in 2024.
• Diluted EPS was $0.96 in 2025, down from $1.58 in 2024.
• Adjusted EBITDA increased to $545.0 million in 2025 from $498.5 million in 2024.
• Medicaid supplemental payment programs contributed $707.5 million in 2025, an increase from $530.3 million in 2024.
• Professional and general liability losses more than doubled to $131.3 million in 2025, compared to $63.0 million in 2024, primarily due to adverse prior period claim developments in New Mexico and social inflationary pressures.
• A change in accounting estimate for accounts receivable collectability resulted in a $42.6 million decrease in revenue in 2025.
• Interest expense decreased to $55.2 million in 2025 from $65.6 million in 2024, mainly due to a $100.0 million prepayment on the Term Loan B Facility in June 2024.
• The company incurred a $7.3 million loss on extinguishment and modification of debt in 2025, up from $3.4 million in 2024.
• Cash and cash equivalents stood at $709.6 million, with available liquidity of $1,004.2 million as of December 31, 2025.
• Capital expenditures for non-acquisitions were $211.9 million in 2025.
• The company completed the acquisition of 18 urgent care clinics in New Mexico and Oklahoma for $27.5 million on January 1, 2025.
• The Term Loan B Facility was refinanced on September 18, 2025, reducing the interest rate by 50 basis points and extending maturity to September 18, 2032.
• The One Big Beautiful Bill Act (OBBBA), passed on July 4, 2025, is expected to reduce federal Medicaid expenditures by approximately $1 trillion over the next decade and tighten Medicaid eligibility.
• The OBBBA also eliminated federal enhanced subsidies for Affordable Care Act (ACA) marketplace exchange-based plans, effective December 31, 2025.
• A securities class action lawsuit and a shareholder derivative action were filed in early 2026, alleging incorrect accounting for accounts receivable and insurance reserves in 2024 and 2025.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a mixed report. While revenue growth and operational efficiency improvements are positive, the significant decline in net income and EPS, coupled with a sharp increase in professional liability losses and the adverse implications of the OBBBA, present considerable headwinds and legal uncertainties.

Positives

• Total revenue increased by 6.0% year-over-year to $6.32 billion in 2025.
• Adjusted admissions grew by 2.3%, indicating increased patient volume.
• Net patient service revenue per adjusted admission increased by 3.5%, reflecting higher reimbursement rates and Medicaid supplemental payments.
• Medicaid supplemental payment programs revenue significantly increased to $707.5 million in 2025 from $530.3 million in 2024.
• Adjusted EBITDA increased to $545.0 million in 2025 from $498.5 million in 2024.
• Adjusted EBITDAR increased to $709.3 million in 2025 from $647.8 million in 2024.
• Successful refinancing of the Term Loan B Facility on September 18, 2025, reducing the interest rate by 50 basis points and extending maturity to September 18, 2032.
• Interest expense decreased to $55.2 million in 2025 from $65.6 million in 2024 due to debt prepayment.
• Acquisition of 18 urgent care clinics in New Mexico and Oklahoma on January 1, 2025, expanding access points.
• Received $21.5 million in business insurance recovery proceeds related to the November 2023 Cybersecurity Incident in 2025.
• Management and independent auditors concluded internal control over financial reporting was effective as of December 31, 2025.
• The OBBBA's tax provisions, including the return to the EBITDA formula for business interest expense limitation and 100% bonus depreciation, are expected to reduce current tax liability.

Negatives

• Net income attributable to Ardent Health, Inc. decreased significantly to $135.8 million in 2025 from $210.3 million in 2024.
• Basic EPS declined to $0.96 in 2025 from $1.59 in 2024.
• Diluted EPS declined to $0.96 in 2025 from $1.58 in 2024.
• Professional and general liability losses more than doubled to $131.3 million in 2025 from $63.0 million in 2024, driven by adverse prior period claim developments in New Mexico and social inflationary pressures.
• A change in accounting estimate for accounts receivable collectability resulted in a $42.6 million decrease in revenue in 2025.
• Other operating expenses, as a percentage of total revenue, increased to 10.3% in 2025 from 8.2% in 2024, primarily due to increased professional and general liability losses and provider assessments.
• Professional fees, as a percentage of total revenue, increased to 18.9% in 2025 from 18.4% in 2024, due to higher costs for hospital-based care providers and rising physician-related expenses.
• The One Big Beautiful Bill Act (OBBBA) is expected to reduce federal Medicaid expenditures by approximately $1 trillion over the next decade and tighten Medicaid eligibility, likely increasing the uninsured population and negatively impacting financial performance.
• The OBBBA eliminated federal enhanced subsidies for ACA marketplace exchange-based plans, effective December 31, 2025, which is likely to result in significant cost increases for ACA plans and adversely impact results in 2026.
• The OBBBA increases the federal deficit, potentially leading to Medicare reimbursement cuts of up to 4% in early 2026 if Congress does not act.
• New securities class action and shareholder derivative lawsuits filed in early 2026 allege incorrect accounting for accounts receivable and insurance reserves in 2024 and 2025, and breaches of fiduciary duties.
• Loss on extinguishment and modification of debt increased to $7.3 million in 2025 from $3.4 million in 2024.

Risks

• Changes in government healthcare programs (Medicare, Medicaid) could adversely affect revenues and business, including reductions in reimbursement levels and supplemental payment programs.
• Reductions in reimbursement rates from commercial payors, increased denials, payment delays, or inability to negotiate favorable contracts.
• Increased volume of uninsured or underinsured patients due to economic conditions or changes in health plan structures.
• Adverse impact from changes in healthcare laws, regulations, policies, and government programs, including the OBBBA's provisions on Medicaid funding, eligibility, and ACA subsidies.
• Security threats, catastrophic events, and other disruptions affecting IT systems, potentially leading to data breaches, legal claims, reputational harm, and business disruption.
• Highly competitive healthcare industry, with trends toward clinical transparency and value-based purchasing impacting competitive position.
• Inability to recruit and retain quality physicians and experienced nurses, leading to increased labor costs and potential capacity limitations.
• Changes to physician utilization practices, treatment methodologies, and the impact of new drugs (e.g., weight loss drugs) could reduce demand for medical services.
• Third-party payor controls (utilization review, prior authorizations, alternative payment models) designed to reduce costs and shift care to outpatient settings may reduce revenues.
• Inability to successfully complete acquisitions or strategic joint ventures (JVs) or realize anticipated benefits, including synergies.
• Risks associated with conducting a significant portion of operations through JVs, including lack of sole decision-making authority and potential conflicts of interest with JV partners.
• Potential requirement to purchase JV partners' equity interests under certain circumstances, which could adversely affect liquidity and financial condition.
• Failure to obtain drugs and medical supplies at favorable prices or in sufficient volumes.
• Operational, legal, and financial risks associated with outsourcing functions to third parties (e.g., revenue cycle management).
• Heavy concentration of facilities in Texas and Oklahoma makes the company sensitive to regulatory, economic, and competitive conditions in those states.
• Negative impact of severe weather, climate change, and other factors beyond control, potentially restricting patient access or causing facility closures.
• Risks related to the Ventas Master Lease, including operating and financial restrictions, cross-acceleration provisions, and purchase options for personal property.
• Significant indebtedness and the ability to refinance it on acceptable terms, limiting capital for operations and growth.
• Exposure to interest rate risk due to variable rate indebtedness.
• Deterioration of public health conditions associated with future pandemics, epidemics, or infectious disease outbreaks.
• Failure to comply with complex laws and regulations applicable to the healthcare industry, leading to penalties, loss of licenses, or exclusion from government programs.
• Government investigations, claims, audits, whistleblower actions, and other litigation.
• Actual or perceived failures to comply with data protection, privacy, and security laws (HIPAA, state laws, AI regulations).
• Inability to or delay in building, acquiring, selling, renovating, or expanding healthcare facilities, including state CON programs and ownership transfer approvals.
• Significant legal and regulatory restrictions on physician-owned hospitals under the Stark Law.
• Tax matters, including disagreements with taxing authorities and imposition of new taxes.
• Costs and management time associated with operating as a public company, including compliance with Sarbanes-Oxley Act.
• Potential conflicts of interest due to controlling stockholders (EGI-AM, Pure Health, Ventas) and their affiliated directors.
• Provisions of Delaware law and governing documents that could discourage takeovers.
• Future sales of common stock by existing stockholders potentially depressing the stock price.
• Lack of or unfavorable research coverage by securities analysts.

Future Outlook

Ardent Health, Inc. expects to grow market share within existing markets and replicate its consumer-centric model across approximately 350 mid-sized urban communities. The company intends to continue investing in high-acuity services, specialty physicians, and ambulatory networks, while advancing capabilities for value-based care and expanding its provider network. Revenue from certain Medicaid supplemental payment programs is expected to decline in 2026 due to program changes, and the elimination of federal enhanced subsidies for ACA marketplace exchange-based plans is anticipated to adversely impact results in 2026, partially offset by ongoing resiliency and cost reduction initiatives. The One Big Beautiful Bill Act (OBBBA) may lead to Medicare reimbursement cuts of up to 4% in early 2026, but its tax provisions are expected to reduce current tax liability.

Management Comments

• We deliver care through a system of 30 acute care hospitals, more than 280 sites of care, and over 2,000 providers that are either employed by or affiliated with us, as of December 31, 2025.
• We hold a leading position in a majority of our markets and believe we are one of the leading healthcare systems based on market share and given our integrated network of hospitals, ambulatory facilities, and physician practices.
• We believe these technologies make it easier for caregivers to focus on delivering care, and for patients to access and receive care across all settings while also improving outcomes, such as safety of care, readmission, and mortality rates.
• We believe we are the JV partner-of-choice for academic medical centers and not-for-profit health systems in new and existing markets.
• At Ardent, culture, safety, quality, and compliance represent the foundation of our platform. We are guided by our operating principles and values, which we define as The Ardent Way.
• We believe that this approach enhances our market share, contributes to a higher quality of care for our patients, increases our operational efficiency, and drives revenue and earnings growth.
• We believe we are currently the only large investor-owned company that has embraced Epic and expect this platform will be highly beneficial to us as the industry moves further into value-based care models, and we believe Epic makes us a more attractive partner for emerging technology providers and facilitates physician use of novel technology.
• We have purposely assembled a world-class leadership team with an average of over 25 years of industry experience and an extensive track record of providing quality care, integrating strategic acquisitions, and driving operational and financial improvements across the enterprise.
• We believe our management teams extensive and diverse experience is a distinct competitive advantage for achieving sustained future success.
• Ardent is committed to driving long-term value creation through a multi-faceted strategy focused on targeted market share growth, operational excellence, and disciplined capital allocation.

Industry Context

StockSavvy.ai notes that the U.S. healthcare industry is a massive and growing sector, with national healthcare expenditures projected to surpass $8.6 trillion by 2033, representing 20.3% of GDP. This growth is fueled by an aging population and increasing prevalence of chronic conditions, creating a robust demand environment for healthcare providers like Ardent. The industry is also undergoing a significant shift towards ambulatory care settings and value-based payment models, driven by efforts to contain costs and improve outcomes. Ardent's strategic focus on expanding its ambulatory network, investing in technology like Epic and AI, and developing value-based care initiatives aligns well with these broader industry trends, positioning it to capitalize on the evolving landscape. However, the industry also faces increasing regulatory scrutiny, particularly regarding price transparency and data privacy, and persistent labor shortages, which could impact operational costs and competitive dynamics.

Comparison to Industry Standards

• Ardent Health's 2025 sepsis bundle compliance rate of 85% resulted in severe sepsis mortality of 2.7% and septic shock mortality of 17.4%, significantly outperforming national averages of approximately 15% and 35%, respectively.
• Nine of Ardent's hospitals received the Leapfrog Group's prestigious 2025 Top Hospital designation.
• 88% of Ardent's graded hospitals received a Fall 2025 Leapfrog Hospital Safety Grade of A or B, compared to the national average of 58% of hospitals.
• The company's early implementation of BioIntelliSense's BioButton wearable technology in certain medical surgical units showed a 15% reduction in mortality in monitored units, while easing nursing workload and reducing length of stay (LOS) by approximately one-third of a day.
• Ardent's system-wide implementation of Epic technology and Gold Stars 9 level designation from Epic indicates a high level of integration and optimization compared to many industry peers, which often struggle with fragmented EHR systems.
• The company's net leverage ratio of 0.8x and lease-adjusted net leverage ratio of 2.5x as of December 31, 2025, suggest a relatively healthy financial position compared to some highly leveraged competitors in the healthcare sector.

Management Changes

Corporate Governance

Legal Proceedings

• Securities Class Action: On January 7, 2026, Postiwala v. Ardent Health, Inc., et al., was filed in the U.S. District Court for the Middle District of Tennessee. The complaint alleges violations of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5, claiming incorrect accounting for accounts receivable and insurance reserves in 2024 and 2025 led to an inflated stock price. The complaint seeks unspecified monetary damages.
• Shareholder Derivative Action: On February 26, 2026, Thompson v Sotir, et al, was filed in the U.S. District Court for the Middle District of Tennessee against certain current officers and directors, with Ardent Health, Inc. as a nominal defendant. The complaint alleges breaches of fiduciary duties, gross mismanagement, waste of corporate assets, unjust enrichment, and violation of Section 14(a) of the Securities Exchange Act of 1934, based on similar factual allegations as the securities class action. It seeks unspecified monetary damages, restitution, and governance reforms.
• Cybersecurity Incident Litigation: Consolidated class action litigation (Hodge v. AHS Management Company, Inc.) related to the November 2023 ransomware attack was settled. The settlement was preliminarily approved on October 9, 2024, and the court ordered its implementation following a hearing on August 1, 2025. Settlement payments did not have a material impact on results of operations, financial position, or liquidity.

Related Party Transactions

• Leases ten hospitals from subsidiaries of Ventas (a related party) under the Ventas Master Lease, which expires in August 2035. Rent expense to Ventas was $152.9 million in 2025.
• Ventas beneficially owned approximately 6.5% of outstanding common stock as of December 31, 2025.
• ALH Holdings, LLC (a subsidiary of Ventas) has the right to nominate one director to the Board as long as it beneficially owns 4% or more of the total voting power.
• The Relative Rights Agreement between Ventas, the senior notes trustee, and administrative agents under senior secured credit facilities sets forth relative rights and caps indebtedness incurred or guaranteed by subsidiaries that are tenants under the Ventas Master Lease at $375.0 million.
• EGI-AM Investments, L.L.C. (EGI-AM) owned approximately 54.1% of outstanding common stock as of December 31, 2025, making it the controlling stockholder with rights to nominate a majority of directors and designate committee chairs.
• An entity affiliated with Pure Health Holding PJSC (Pure Health) beneficially owned approximately 21.2% of outstanding common stock as of December 31, 2025.
• Four directors are affiliated with EGI, potentially creating conflicts of interest.
• The company's certificate of incorporation renounces its interest in certain corporate opportunities, allowing EGI-AM and Ventas affiliates to pursue opportunities complementary to the business.

Stakeholder Impact

• Shareholders: Negative impact from significant decline in net income and EPS, increased professional liability losses, and new securities litigation. Potential for stock price volatility. Controlled company status and corporate opportunity renunciation provisions may limit protections.
• Patients: Continued focus on consumer-centric care, quality, and safety (e.g., high sepsis compliance, Leapfrog ratings). Expansion of ambulatory and telehealth services aims to improve access and continuity of care. However, potential for reduced access to care due to Medicaid eligibility tightening and ACA subsidy elimination under OBBBA.
• Employees: Dependence on skilled management and medical support personnel. Labor shortages and increased competition for staffing could lead to higher labor costs. Investment in training and development programs.
• Payors (Governmental): Significant impact from the OBBBA, which is projected to reduce federal Medicaid expenditures by $1 trillion over the next decade and potentially lead to Medicare cuts. Changes to Medicaid eligibility and SDP arrangements will affect reimbursement.
• Payors (Commercial): Continued demand for discounted fee structures and cost controls. Consolidation among payors increases their bargaining power. No Surprises Act impacts out-of-network billing.
• Creditors: Significant indebtedness ($294.6M senior notes, $764.2M term loan, $40.4M finance leases). Debt covenants and restrictions. Refinancing of Term Loan B Facility extended maturity and reduced interest rate, which is positive.

Next Steps

• Continue to build a leading position in existing markets by investing in high-acuity services, specialty physicians, and ambulatory networks.
• Further optimize the network via transfer center operations to improve care navigation and coordination.
• Advance capabilities to succeed in a value-based care environment and expand participation in these programs.
• Grow the extensive and diverse provider network through robust recruitment of primary care and specialist physicians.
• Leverage Epic and other technology solutions to track and segment consumers for patient outreach, acquisition, and engagement initiatives.
• Opportunistically expand into new regional, mid-sized urban markets through acquisitions and partnership opportunities, particularly JVs with not-for-profit and academic health systems.
• Vigorously defend against the recently filed securities class action and shareholder derivative lawsuits.
• Monitor and adapt to the implementation and impact of the One Big Beautiful Bill Act (OBBBA) and other regulatory changes, including potential Medicare cuts and changes to Medicaid and ACA subsidies.
• Evaluate the impact of ASU 2024-03 and ASU 2025-06 on future disclosures.

Key Dates

Recommendation

Ardent Health, Inc. demonstrates solid revenue growth and operational improvements, including increased patient volumes and effective technology adoption. However, the significant decline in net income and EPS, coupled with a substantial increase in professional liability losses and the adverse financial implications of the OBBBA on Medicaid and ACA subsidies, introduce considerable uncertainty and risk. The ongoing securities litigation further adds to potential financial and reputational headwinds. Given these mixed signals and the regulatory challenges, a "hold" recommendation is appropriate as investors await clearer indications of how the company will navigate these pressures and whether its growth strategies can offset the rising costs and regulatory impacts.

Keywords

Healthcare services, Hospital operations, Acute care, Ambulatory care, Joint ventures, 10-K, Financial results, Revenue growth, Net income, Adjusted EBITDA, Medicaid supplemental payments, Professional liability, Cybersecurity, Ransomware, Regulatory changes, OBBBA, ACA subsidies, Physician employment, Labor costs, Value-based care, Epic EHR, AI in healthcare, Debt refinancing, Securities litigation, Shareholder derivative action, Ventas Master Lease, Texas healthcare, Oklahoma healthcare, New Mexico healthcare, New Jersey healthcare, Idaho healthcare, Kansas healthcare